Pharma Mar Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Pharma Mar stock has a consensus rating of "Buy" and an average price target of €111.56. The average 1-year stock price forecast is 60.52% higher than the current stock price, while the lowest is €90.00 (+29.50%) and the highest is €125.00 (+79.86%).

Price Target: €111.56 (+60.52%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	€90.00	€111.56	€120.00	€125.00
Change	+29.50%	+60.52%	+72.66%	+79.86%

Analyst Ratings

The average analyst rating for Pharma Mar stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	6	6	6
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Keay Nakae Chardan Capital	Chardan Capital	Buy Maintains €120.00	Buy	Maintains	€120.00	+72.66%	Jun 8, 2026
Kambiz Yazdi BTIG	BTIG	Buy Initiates €121.00	Buy	Initiates	€121.00	+74.10%	Apr 23, 2026

Financial Forecast

Revenue This Year

212.46M

from 221.39M

-4.03%

from 221.39M

Revenue Next Year

300.28M

from 212.46M

41.34%

from 212.46M

EPS This Year

2.38

from 4.30

-44.73%

from 4.30

EPS Next Year

6.24

from 2.38

162.41%

from 2.38

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	229.83M	196.34M	158.15M	174.86M	221.39M	212.46M
Revenue Growth	-14.87%	-14.57%	-19.45%	10.56%	26.61%	-4.03%
Gross Profit	213.39M	182.70M	148.54M	166.67M	209.13M	200.19M
Gross Margin	92.85%	93.05%	93.92%	95.32%	94.46%	94.23%
Operating Income	92.45M	42.07M	-3.83M	6.47M	60.72M	50.94M
Net Income	92.86M	49.36M	1.14M	26.13M	74.99M	49.08M
EPS	-	-	-	-	4.30	2.38
EPS Growth	-	-	-	-	188.59%	-44.73%
Forward PE	12.76	16.74	67.76	36.29	24.03	29.24
Dividend / Share	0.65	0.65	0.65	0.80	-	0.97
Free Cash Flow	4.75M	33.11M	-12.59M	-20.15M	22.88M	48.84M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	245.0M
Avg	212.5M
Low	151.4M

Revenue Growth

Revenue Growth	2026	2027	2028
High	10.7%
Avg	-4.0%
Low	-31.6%

EPS Forecast

EPS	2026	2027	2028
High	4.11
Avg	2.38
Low	-0.91

EPS Growth

EPS Growth	2026	2027	2028
High	-4.4%
Avg	-44.7%
Low	-